چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده ثبت کننده مقاله | محمد عباسعلیزاده |
| مرحله جاری مقاله | تایید نهایی |
| دانشکده/مرکز مربوطه | کمیته تحقیقات دانشجویی |
| کد مقاله | 86478 |
| عنوان فارسی مقاله | اثر داروهای مهار کننده 4 Toll-like receptor بر اندازه حجم انفارکتوس و عملکرد عصبی در مدل های سکته مغزی ایسکمیک جوندگان: مطالعه مروری نظام مند و متاآنالیز |
| عنوان لاتین مقاله | Impact of Toll-like receptor 4 inhibitor agents on the size of infarction volume and neurological functions in rodent ischemic stroke models: a systematic review and meta-analysis |
| نوع ارائه | پوستر |
| عنوان کنگره / همایش | 13th Neuroscience congress 2024 |
| نوع کنگره / همایش | ملی |
| کشور محل برگزاری کنگره/ همایش | |
| شهر محل برگزاری کنگره/ همایش | تهران |
| سال انتشار/ ارائه شمسی | 1403 |
| سال انتشار/ارائه میلادی | 2024 |
| تاریخ شمسی شروع و خاتمه کنگره/همایش | 1403/09/21 الی 1403/09/23 |
| آدرس لینک مقاله/ همایش در شبکه اینترنت | http://bcncongress.ir |
| آدرس علمی (Affiliation) نویسنده متقاضی | Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. |
| نویسنده | نفر چندم مقاله |
|---|---|
| محمد عباسعلیزاده | اول |
| رسا بهشتی | دوم |
| امیرحسین بهرامی | سوم |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Background and Aims: The phenomenon of reperfusion following cerebral ischemia triggers the release of cellular stress-induced molecules termed Damage-Associated Molecular Patterns (DAMPs), which subsequently initiate an inflammatory response and contribute to ischemic reperfusion injury (IRI). Recent research has revealed the critical importance of Toll-like Receptors (TLRs), especially TLR4, in the development of IRI. A variety of in vivo research has demonstrated the efficacy of several anti-TLR4 agents in attenuating IRI. The current investigation aims to deliver a comprehensive analysis of the safety and efficacy of anti-TLR4 agents in animal model studies. Methods: A systematic search was conducted across databases including PubMed, Scopus, Web of Science, and Embase. The resultant findings were independently screened by two authors. Our inclusion criteria encompassed in vivo studies that evaluated either direct TLR4 antagonists or agents primarily inhibiting TLR4 expression in models of Middle Cerebral Artery Occlusion (MCAO) or Common Carotid Artery Occlusion. The assessment of bias risk in the included studies was executed by two authors independently utilizing the CAMARADES criteria. Results: Following the elimination of duplicate entries and screening following our inclusion criteria, a total of six studies were identified for inclusion. The administration of MTS510, recognized as an anti-TLR4 antibody, miR-542-3p, functioning as a TLR4 expression inhibitor, ApTLR#4F and ApTLR#4FT, classified as TLR4-blocking DNA aptamers, TAK-242 and Eritoran (E5564) as TLR4 antagonists, along with the intracerebroventricular injection of Resatorvid as a TLR4-NOX4 signaling inhibitor in the MCAO murine model resulted in a statistically significant reduction in infarction volume and enhancement in neurological function. |
| کلمات کلیدی |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| tlr4.png | 1403/10/12 | 1267125 | دانلود |
| parti.png | 1403/10/12 | 1966918 | دانلود |
| 19 new.jpg | 1403/10/12 | 3505240 | دانلود |
| CamScanner 09-23-2024 14.48_1.jpg | 1403/10/12 | 290269 | دانلود |
